SDS Optic Spolka Akcyjna
4.00
PLN
-0.14
(-3.38%)
ISIN
PLSDSOP00013
Return %
Stock
S&P 500
1Y
-52.83
14.20
3Y
-88.10
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Marcin Staniszewski
- Full Time Employees
- 29
- Sector
- Electronic technology
- Industry
- Semiconductors
- Address
- Lublin Poland
- IPO Date
- Mar 15, 2022
- Website
- sdsoptic.pl
- Similar Companies
- Business
- SDS Optic Spolka Akcyjna operates as a clinical-stage medical technology and deep tech company that develops, manufactures, and commercializes real-time diagnostic and therapeutic monitoring solutions integrating photonics, molecular biology, advanced materials, and immunochemistry. The company's core technology and service portfolio include the inPROBE platform, a patented fiber-optic micro-biosensor designed for real-time, in vivo numerical measurement of specific cancer biomarkers such as HER2 without requiring surgical tissue extraction; custom monoclonal and anti-idiotype antibody engineering services for biological research and clinical applications; and multifunctional optical nanolayer coatings engineered for thermal dissipation, barrier protection, and biocidal properties across medical and industrial sectors. SDS Optic serves oncology clinics, diagnostic laboratories, healthcare systems, and biopharmaceutical developers primarily in Europe and North America. The company conducts research, optoelectronic development, and manufacturing through its headquarters in Lublin, Poland, its biomarker research subsidiary SDS Optic Inc. in Philadelphia, Pennsylvania, and its infectious disease technology subsidiary FiBioMed Sp. z o.o. Founded in 2013, SDS Optic Spolka Akcyjna is headquartered in Lublin, Poland, and is listed on the Warsaw Stock Exchange. In recent developments, the company secured a venture debt financing facility of up to 10 million euros from the European Investment Bank under the InvestEU initiative to support research and scale-up operations; completed Phase I safety and feasibility clinical trials for HER2 breast cancer detection and advanced strategic adjustments for subsequent clinical testing; formed a collaborative development project with Accrea Medical Robotics and MedApp S.A. to combine optical micro-biosensors with robotic biopsy systems; joined the Medical Forge Leipzig accelerator to support German market expansion; and signed development contracts with United States partners for the supply of proprietary biological components.